Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial

Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A newer revision tag was added (v3.5.4) and the previous revision tag (v3.5.3) was removed, signaling an updated version of the study record.
    Difference
    0.1%
    Check dated 2026-05-15T06:51:35.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page footer’s site revision indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a platform/release change rather than any change to the trial information.
    Difference
    0.1%
    Check dated 2026-04-24T06:36:35.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:54:36.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed.
    Difference
    0.1%
    Check dated 2026-03-19T06:40:41.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T00:30:43.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the page.
    Difference
    0.1%
    Check dated 2026-02-25T18:23:41.000Z thumbnail image

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.